On April 15, 2026, Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, announced the closing of a $108 million Series C financing round. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, and participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. Wilson Sonsini Goodrich & Rosati advised Terremoto on IP matters related to the transaction.

Proceeds from the financing will be used to advance Terremoto’s lead AKT1-selective inhibitor programs through Phase 1 clinical development for patients with cancer and rare diseases such as hereditary hemorrhagic telangiectasia.

The Wilson Sonsini team that advised Terremoto on IP matters related to the transaction includes Julia Minitti, Luis Perla, and Jane Yang.

For more information, please see Terremoto’s news release. Additional coverage can be found on Fierce Biotech.